Forgot Password?
Return to Course Listing

CME: Mesothelioma management: Therapeutic updates and best practices

Activity Description / Statement of Need:

In this online, self-learning activity:

Mesothelioma is a malignancy that occurs in mesothelium, an epithelial layer that lines the pleurae, peritoneum, pericardium, the testes’ tunica vaginalis and tunica serosa uteri. Malignant mesothelioma (MM) may occur in any area that is composed of mesothelial cells, but the most common site is in the pleural space (81%) in cases of malignant pleural mesothelioma (MPM), followed by peritoneum (9%).. In United States, approximately 3,200 new cases of MM are diagnosed each year, and it mostly affects older white male with median age of 62 at diagnosis for MPM and a slightly younger median age for peritoneal MM. Whites are twice as likely to develop MM as blacks, and males are four times as likely as females. The largest risk factor for MM is a history of asbestos exposure: over 80% of MPM patients and 33% of patients with peritoneal MM have a documented prior exposure.


Target Audience:

Healthcare professionals including: medical oncologists, primary care physicians, and pathologists; physicians assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with mesothelioma.

This program is supported by educational grants from Novacure.

This activity is free of charge.

Release Date: June 15, 2021 -- Expiration Date: June 15, 2023

Faculty: Robert Cameron, MD


Epidemiology, risk factors, and different types of mesothelioma

  • Incidence, histology, pathophysiology, and prognosis of mesothelioma
  • Risk factors, including: asbestos exposure, race, age, gender 
  • Types of mesothelioma 
  • Complications and burden associated with mesothelioma 

Diagnosis and treatment of mesothelioma

  • Guideline-recommended and data-supported updates in the diagnosis and treatment of mesothelioma
  • Limitations of current diagnostic tools
  • Present standards of care in the treatment of mesothelioma and limitations, including outcomes
  • Emerging, investigational therapies, including oral angiokinase inhibitors and tumor treating fields
  • Patient case(s)

Learning Objectives

By the end of the session the participant will be able to:

  • Review the incidence, diagnosis, and histology of mesothelioma
  • Describe the pathology of pleural mesothelioma and the roles of angiogenesis and associated growth factor signaling pathways
  • Describe existing unmet needs in improving outcomes for patients with mesothelioma, including prolonging progression-free and overall survival
  • Describe present standards of care in the treatment of patients with mesothelioma and apply them to patient cases
  • Describe emerging therapies for mesothelioma and the data behind them, including anti-angiogenic agents, such as oral angiokinase inhibitors, and tumor treating fields


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physicians: If this activity does not specify that it provides MOC credit in this section, then it does NOT provide MOC credit.


ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-22-037-H01-P.  This is a Knowledge (K)-type activity. 

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.  ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure:  Robert Cameron, MD, discloses that he is a stockholder in Volition Rx LTD and on a scientific advisory board for Novocure.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, has no relevant financial disclosures.

Commercial Support Disclosure: This program is supported by educational grants from Novocure.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Metastatic Colon Cancer: Updates from the 2020 ASCO (American Society of Clinical Oncology) Annual Meeting

Treating Oncology Patients During COVID-19

Advances in Treating Triple-Negative Metastatic Breast Cancer: Optimizing Pharmacotherapeutic Management Strategies

Addressing skeletal-related events in prostate cancer